fda glp-1 compounding crackdown news october 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Compounded GLP-1s: Why doctors worry

This once-weekly injectable is part of the trusted Wegovy protocol, FDA-approved for chronic weight management in adults with obesity or weight-related health conditions

Our concern is patients who lose weight quickly and without significantly changing their lifestyle are prone to gaining more weight once they stop.

PrecisionLife and Ovation are developing a test to predict GLP-1 drug response, enabling precision prescribing and sustainable access to these therapies.

Youll learn why these drugs may be effective in the short term but fall short of addressing the root causes of obesity and metabolic dysfunction

However, that is not the reality: even diabetic patients treated with GLP-1 RAs are more likely to stop them than other second-line anti-diabetic medicines.3 That study didnt report why 50% of diabetics on GLP-1 RAs discontinued them, but gastrointestinal (GI) adverse events were a suggested cause.3 Adverse events are just one of a number of reasons that people stop using these drugs, as follows.